PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

NCT04815408 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Neoadjuvant Chemotherapy
Anti-PD-1
Neoadjuvant Immunotherapy

Interventions

DRUG: BGB-A317
DRUG: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University